16 Introduction: The aim of this study was to investigate whether there is an increased susceptibility to apoptosis in cultured 17 fibroblasts from patients with schizophrenia. 18 Method: Dermal fibroblasts were collected and cultured from three groups: patients with schizophrenia, patients with non-19 schizophrenic psychosis, and healthy comparison subjects. Susceptibility to apoptosis was measured at the level of degradation 20 product (proportion of cells in the sub-G0 cell cycle fraction in which apoptotic bodies accumulate), pro-apoptotic effector 21 (activated caspase-3), and molecular regulators (P53, Bax and Bcl-2). Cell lines were studied under both basal culture and 22 cycloheximide (an apoptotic inducer) exposure conditions. 23 Results: Consistent with increased susceptibility to apoptosis, the proportion of sub-G0 cells under basal conditions was 24 significantly larger in the schizophrenia group, compared to the non-schizophrenic psychosis group. However when apoptosis 25 was stimulated with cycloheximide, the schizophrenia group showed an attenuated caspase-3 response. The pattern of 26 correlations between regulators, caspase-3 and the proportion of sub-G0 cells was different in the schizophrenia group, 27 consistent with group-specific apoptotic pathway dysregulation.
U N C O R R E C T E D P R O O F
35
The evidence of reduced incidence rates of cancer 36 in schizophrenia (for a recent review, see Grinshpoon 37 et al., 2005) was advanced in support of the 38 hypothesis that increased susceptibility to apoptosis 39 is implicated in the pathophysiology of schizophrenia 40 (Catts and Catts, 2000) . The rationale for this proposal 41 was based upon the role of apoptosis in protecting 42 against malignancy. Apoptotic regulators check DNA 43 integrity at all stages of the cell cycle. If DNA damage 44 is detected, cell cycle progression is arrested to allow 45 repair of damaged DNA. If DNA repair is not 46 possible, the potentially pre-cancerous cell normally 47 undergoes apoptosis and is eliminated.
48
The current study was designed to carry out a 49 multi-level functional assessment of apoptosis in 50 living cells-at the level of regulators (P53, Bax 51 and Bcl-2), effectors (caspase-3), and degradation 52 products (apoptotic bodies). Phosphorylation of the 53 transcription factor P53 increases levels of the pro-54 apoptotic protein Bax. Homodimerisation of Bax 55 results in mitochondrial release of cytochrome C, 56 which activates proteolytic enzymes called caspases in 57 the cytosol. Caspase activation leads to DNA frag-58 mentation and cell death. As the dying cell shrinks, 59 the plasma membrane forms convolutions around 60 cellular contents (dblebbingT), which sequester to form 61 dapoptotic bodiesT containing DNA fragments. The 62 anti-apoptotic protein, Bcl-2 keeps this process in 63 check by forming Bax-Bcl-2 heterodimers, preventing 64 Bax-Bax Homodimerisation.
65
We measured apoptotic markers in cultured dermal 66 fibroblasts, based on the assumption that systemic 67 cancer resistance would be related to altered apoptotic 68 mechanisms in all cell types. Cultured dermal 69 fibroblasts have been demonstrated to be a convenient 70 and useful model for investigating schizophrenia 71 (Mahadik and Mukherjee, 1996 (McGrath et al., 2000) . Subjects 89 were assessed with the Diagnostic Interview for 90 Psychosis (Jablensky et al., 1999) 
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Treatment effects on caspase activity levels for 234 each diagnostic group can be seen in Fig. 2 . 235 Cycloheximide exposure had a significant effect on 236 caspase activity ( F = 27.823, df = 1, 29, p = 0.000). 237 The average caspase activity across-groups increased 238 from 4 to 11 AM AFC/h/Ag protein with cyclohexi-239 mide exposure. There was no statistically significant 240 change in levels of phosphorylated P53
P392Ser with 241 treatment ( F = 2.714, df = 1, 29, p = 0.105), although it 242 increased numerically from 0.7 to 0.9 optical density 243 units. Also, there was no statistically significant effect 244 of cycloheximide exposure on Bcl-2 or Bax protein 245 levels, or on Bcl-2:Bax ratios (see Fig. 3 ).
246

Diagnostic group effects
247
The MANOVA detected a significant effect of 248 diagnostic group on the proportion of cells in sub-G0 249 ( F = 3.487, df = 2, 59, p = 0.037). Tukey's post-hoc 250 test revealed that this effect was due to a significant 251 increase ( p = 0.029) in the proportion of cells in sub-252 G0 in the schizophrenia group compared to the NSP 253 group (basal and cycloheximide exposure conditions 254 combined), whilst there was no difference between the 255 healthy comparison group and the NSP group on this 256 measure ( p = 0.515). As can be seen in Fig. 1 , this 257 result was mainly attributable to a significant increase 258 in the basal level of sub-G0 cells (t = 2.117, p = 0.024, 259 one-tailed) in the schizophrenia group (6.4%) com-260 pared with the NSP group (2.8%), though this effect 261 was apparent at the level of a trend in the cyclohex-262 imide exposed cells (5.1% versus 3.9%; t = 1.443, 263 p = 0.083, one-tailed). There was a trend for the basal 264 level of sub-G0 cells to be increased in the schizo-265 phrenia group (6.4%) compared with the healthy 266 comparison group (3.8%), though again this trend did 267 not achieve conventional levels of statistical signifi-268 cance (t = 1.395, p = 0.090, one-tailed). In the cyclo-269 heximide exposed cells, there was no difference in the 270 proportion of sub-G0 cells between the schizophrenia 271 and healthy comparison groups (5.1% versus 5.6%; 272 t = À 0.443, p = 0.33, one-tailed).
273 Although the MANOVA did not detect a statisti-274 cally significant effect of diagnostic group on caspase 275 activity, there was evidence of an effect at trend level 276 ( F = 2.994, df = 2, 59, p = 0.06). Visual inspection of 277 Fig. 2 suggested that there was no difference in 278 caspase-3 activity levels between the three diagnostic 279 groups under basal conditions, but there was a 280 difference in the cycloheximide exposure condition.
281 An exploratory post-hoc t-test revealed, contrary to 282 hypothesis, that the schizophrenia group had signifi-283 cantly less caspase-3 activity compared to the healthy 284 comparison group in the cycloheximide exposed 285 samples (t = À 2.246, p = 0.038, two-tailed). 
There was no statistically significant effect of 287 diagnostic group for the level of phosphorylated 288 P53 PSer392 protein ( F = 0.448, df = 2, 59, p = 0.64), 289 level of Bcl-2 protein ( F = 0.394, df = 2, 59, p = 0.68), 290 level of Bax protein ( F = 2.089, df = 2, 59, p = 0.13), or 291 for the ratio of Bcl-2:Bax protein ( F = 1.177, df = 2, 292 59, p = 0.32). Inspection of the Fig. 3 graph headed 293 Bcl-2:Bax reveals that the Bcl-2:Bax ratio was 294 numerically lower in cells under both basal and 295 cycloheximide exposure conditions in the schizophre-296 nia group compared with the other two groups, but 297 post-hoc testing did not detect significant group 298 differences. 
300
Assay intercorrelations were determined to assess 301 whether the relationships between markers conformed 302 to what is known about apoptotic pathways, and to 303 explore group differences in these relationships. When 304 bivariate correlation coefficients were calculated for 305 apoptotic markers across diagnostic groups separately 306 for cells under basal and cycloheximide exposure 307 conditions, there were no significant correlations 308 between: phosphorylated P53 PSer392 and Bax levels; 309 Bax levels and caspase-3 activity; and caspase-3 310 activity and the proportion of cells in sub-G0. 311 Within-group intercorrelations between apoptotic 312 markers are presented in Table 1 . There are distinct 313 diagnostic group differences in the overall pattern of 314 relationships. Under basal conditions there are signif-315 icant negative correlations between Bax levels and the 316 Bcl-2:Bax ratio (and the absence of such a relation-317 ship between Bcl-2 levels and the Bcl-2:Bax ratio) in 318 the healthy comparison group and the NSP group; 319 whereas in the schizophrenia group, there is a 320 significant positive correlation between Bcl-2 levels 321 and the Bcl-2:Bax ratio (and the absence of such a 322 relationship between Bax levels and the Bcl-2:Bax 323 ratio). In the cycloheximide exposure condition, Bax 324 levels are significantly negatively correlated with the 325 Bcl-2:Bax ratios in each of the three subject groups. 326 However, the expected positive correlations between 327 Bax levels and caspase-3, and caspase-3 and sub-G0, 328 are only evident in the healthy comparison group and 329 the NSP group. In the schizophrenia group correla- 
333
The central aim of the present study was to test in a 334 dermal fibroblast cell model the hypothesis that there is 335 an increased susceptibility to apoptosis in schizophre-336 nia. Supporting this hypothesis, we found an increased 337 proportion of cells in the sub-G0 fraction of the cell 338 cycle under basal culture conditions in the schizophre-339 nia group compared to the NSP group. This measure 340 was not significantly different in the NSP group 341 compared to the healthy comparison group. As it is 342 well established that apoptotic cell bodies accumulated 343 in sub-G0, we interpreted this finding as being 344 consistent with patients with schizophrenia showing 345 increased basal susceptibility to apoptosis. This inter-346 pretation is supported by the finding that the Bcl-2:Bax 347 ratio was numerically lower in the schizophrenia group 348 compared to the other groups, consistent with an 349 increased proneness to apoptosis in the schizophrenia 350 patient fibroblasts (Adams and Cory, 1998) .
351
There were no differences in caspase-3 activity 352 across the three diagnostic groups under basal con-353 ditions. This finding is comparable to Jarskog et al. 354 (2004) , who did not find a significant difference in the 355 level of caspase-3 in a postmortem tissue study of 356 temporal cortex in patients with schizophrenia com-357 pared with healthy controls. In the cycloheximide 358 exposed cell lines there was a strong trend (statistically 359 significant on post-hoc testing) for patients with 360 schizophrenia to have decreased caspase-3 activity 361 compared with healthy controls. Hence, our findings 362 concerning caspase activity are not consistent with 363 increased susceptibility to apoptosis in patients with 364 schizophrenia, unless this susceptibility is caspase-3 365 independent. For instance, this form of susceptibility to 366 apoptosis could be mediated by another caspase. 367 Alternatively, caspase-independent susceptibility could 368 be mediated by the apoptosis-inducing factor (AIF), 369 which is essential for programmed cell death during 370 cavitation of embryoid bodies (Joza et al., 2001 
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375 the Bcl-2:Bax ratio was primarily determined by Bcl-376 2 levels in the schizophrenia group, in contrast to the 377 two control groups where Bax was the primary 378 determinant of the Bcl-2:Bax ratio. In the cyclohex-379 imide exposure condition the expected positive 380 correlations between Bax levels and caspase-3, and 381 caspase-3 and sub-G0, found in the two control 382 groups, were both negative in the schizophrenia 383 group. This pattern of findings may account for the 384 unexpected reduction in caspase-3 activity, and the 385 attenuated increase in the sub-G0 cell fraction, in the 386 schizophrenia group cultures under cycloheximide 387 exposure conditions. 388 There were limitations with the cell model used. 389 Dermal fibroblasts were chosen because they can be 390 induced to proliferate in vitro, and antipsychotic 391 medication effects can be minimised or eliminated 392 by maintaining the culture for many cell passages. 393 However, they do not appear to be readily suscep-394 tible to apoptotic cell death. In pilot testing, 
